Identifying BRAF and KIT mutations in melanoma

References

• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809–819 (2010).
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial. Lancet 380(9839), 358–365 (2012).
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366(8), 707–714 (2012).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P et al.; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367(2), 107–114 (2012).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367(18), 1694–1703 (2012).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24(26), 4340–4346 (2006).
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD et al. KIT as a therapeutic target in metastatic melanoma. JAMA 305(22), 2327–2334 (2011).
   PubMed Web of Science ®Google Scholar
• Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. 29(21), 2904–2909 (2011).
   PubMed Web of Science ®Google Scholar
• Minor DR, Kashani-Sabet M, Garrido M, O’Day SJ, Hamid O, Bastian BC. Sunitinib therapy for melanoma patients with KIT mutations. Clin. Cancer Res. 18(5), 1457–1463 (2012).
   PubMed Web of Science ®Google Scholar
• Rubinstein JC, Sznol M, Pavlick AC et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J. Transl. Med. 8, 67 (2010).
   PubMed Web of Science ®Google Scholar
• Tan YH, Liu Y, Eu KW et al. Detection of BRAF V600E mutation by pyrosequencing. Pathology 40(3), 295–298 (2008).
   PubMed Web of Science ®Google Scholar
• Ichii-Nakato N, Takata M, Takayanagi S et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J. Invest. Dermatol. 126(9), 2111–2118 (2006).
   PubMed Web of Science ®Google Scholar
• Lin J, Goto Y, Murata H et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br. J. Cancer 104(3), 464–468 (2011).
   PubMed Web of Science ®Google Scholar
• Yancovitz M, Litterman A, Yoon J et al. Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS ONE 7(1), e29336 (2012).
   PubMed Web of Science ®Google Scholar
• Pinzani P, Santucci C, Mancini I et al. BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin. Chim. Acta. 412(11–12), 901–905 (2011).
   PubMed Web of Science ®Google Scholar
• Kim TE, Jung ES, Jung CK et al. DHPLC is a highly sensitive and rapid screening method to detect BRAF(V600E) mutation in papillary thyroid carcinoma. Exp. Mol. Pathol. 94(1), 203–209 (2013).
   PubMed Web of Science ®Google Scholar
• Kim SK, Kim DL, Han HS et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn. Mol. Pathol. 17(2), 118–125 (2008).
   PubMed Web of Science ®Google Scholar
• Shackelford W, Deng S, Murayama K, Wang J. A new technology for mutation detection. Ann. NY Acad. Sci. 1022, 257–262 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson S, Bloom KJ, Vallera DU et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch. Pathol. Lab. Med. 136(11), 1385–1391 (2012).
   PubMed Web of Science ®Google Scholar
• Jiang W, Wang W, Fu F et al. A more sensitive platform for the detection of low-abundance BRAF(V600E) mutations. Mol. Cell Biochem. 366(1–2), 49–58 (2012).
   PubMed Web of Science ®Google Scholar
• Tiacci E, Schiavoni G, Forconi F et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 119(1), 192–195 (2012).
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472–480 (2002).
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544), 1329–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem. Pharmacol. 80(5), 568–574 (2010).
   PubMed Web of Science ®Google Scholar
• Chi Z, Li S, Sheng X et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11, 85 (2011).
   PubMed Web of Science ®Google Scholar
• Ishihara K, Saida T, Otsuka F, Yamazaki N; Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int. J. Clin. Oncol. 13(1), 33–41 (2008).
   PubMed Web of Science ®Google Scholar
• Torres-Cabala CA, Wang WL, Trent J et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod. Pathol. 22(11), 1446–1456 (2009).
   PubMed Web of Science ®Google Scholar
• Liegl B, Kepten I, Le C et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 216(1), 64–74 (2008).
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 99(5), 929–935 (2008).
   PubMed Web of Science ®Google Scholar
• Colombino M, Capone M, Lissia A et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30(20), 2522–2529 (2012).
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287), 431–435 (2010).
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287), 427–430 (2010).
   PubMed Web of Science ®Google Scholar
• Sakaizawa K, Goto Y, Kiniwa Y et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br. J. Cancer 106(5), 939–946 (2012).
   PubMed Web of Science ®Google Scholar
• Terheyden P, Houben R, Pajouh P, Thorns C, Zillikens D, Becker JC. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J. Invest. Dermatol. 130(1), 314–316 (2010).
   PubMed Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10(20), 6897–6904 (2004).
   PubMed Web of Science ®Google Scholar
• Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the ‘leukemic phase’ of solid cancers. Trends Mol. Med. 12(3), 130–139 (2006).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Kitago M, Koyanagi K, Nakamura T et al. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin. Chem. 55(4), 757–764 (2009).
   PubMed Web of Science ®Google Scholar
• Suesskind D, Ulmer A, Schiebel U et al. Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study. Acta Ophthalmol. 89(1), 17–24 (2011).
   PubMed Web of Science ®Google Scholar
• Ulmer A, Fierlbeck G. Circulating tumor cells and detection of the melanoma-associated antigen HMW-MAA in the serum of melanoma patients. J. Invest. Dermatol. 126(4), 914–915; author reply 915–916 (2006).
   PubMed Web of Science ®Google Scholar
• Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit. Rev. Immunol. 24(4), 267–296 (2004).
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011).
   PubMed Web of Science ®Google Scholar
• Jaiswal BS, Janakiraman V, Kljavin NM et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS ONE 4(5), e5717 (2009).
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Bezrookove V, Green G et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229), 599–602 (2009).
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Griewank KG, Crosby MB et al. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363(23), 2191–2199 (2010).
   PubMed Web of Science ®Google Scholar
• Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS ONE 7(1), e29622 (2012).
   Google Scholar
• Ho AL, Musi E, Ambrosini G et al. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS ONE 7(7), e40439 (2012).
   PubMed Web of Science ®Google Scholar
• Prickett TD, Agrawal NS, Wei X et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41(10), 1127–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Settleman J. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin. Cancer Cell 16(4), 278–279 (2009).
   PubMed Web of Science ®Google Scholar
• Dutton-Regester K, Irwin D, Hunt P et al. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol. Cancer Ther. 11(4), 888–897 (2012).
   PubMed Web of Science ®Google Scholar
• Lovly CM, Dahlman KB, Fohn LE et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE 7(4), e35309 (2012).
   PubMed Web of Science ®Google Scholar